Letters to the Editor
Rituximab-Induced Acute Pulmonary Fibrosis

https://doi.org/10.4065/79.7.949Get rights and content

REFERENCES (2)

  • JC Byrd et al.

    Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

    J Clin Oncol

    (1999)
  • P McLaughlin et al.

    Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapse indolent lymphoma: half of patients respond to a four-dose treatment program

    J Clin Oncol

    (1998)

Cited by (47)

  • Pulmonary Complications of Anticancer Treatment

    2013, Abeloff's Clinical Oncology: Fifth Edition
  • Rituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage: A case report

    2011, Journal of Experimental and Clinical Medicine
    Citation Excerpt :

    Rituximab, a chimeric monoclonal antibody targeting CD20, is widely used in the treatment of B-cell neoplasms.1–5 But some unexpected adverse effects with lethal potential may occur in patients treated with rituximab,6–9 which probably impede its further use. Recently, much attention has been paid to acute respiratory reactions, including interstitial pneumonitis,9–14 bronchiolitis obliterans with organizing pneumonia (BOOP),15,16 diffuse alveolar hemorrhage8–10 and pulmonary fibrosis.7

  • Pulmonary complications of cancer therapy and central airway obstruction

    2011, Supportive Oncology: (Expert Consult - Online and Print)
View all citing articles on Scopus
View full text